But abstinence is often a higher bar akin to demanding that an antidepressant develop total remission of depression or that an analgesic completely get rid of discomfort. Recognizing this limitation, the FDA encourages developers of opioid2 and stimulant3 use disorder remedies to discuss with FDA alternate approaches to evaluate modifications https://www.sgvascularctr.com/what-is-clacs/